TG Therapeutics, Inc. (NASDAQ:TGTX) went up by 4.25% from its latest closing price when compared to the 1-year high value of $25.02 and move up 3.25%, while TGTX stocks collected 8.66% of gains with the last five trading sessions. Press Release reported on 08/13/20 that TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma
TG Therapeutics, Inc. (NASDAQ:TGTX) Worth an Investment?
TG Therapeutics, Inc. (NASDAQ: TGTX) The 36 Months beta value for TGTX stocks is at 2.33, while 7 of the analysts out of 7 who provided ratings for TG Therapeutics, Inc. stocks as a “buy” while 0 as overweight, 0 rated it as hold and 0 as sell. The average price we get from analysts is $39.29 which is $13.64 above current price. TGTX currently has a short float of 16.38% and public float of 93.68M with average trading volume of 1.66M shares.
TGTX Market Performance
TGTX stocks went up by 8.66% for the week, with the monthly jump of 24.27% and a quarterly performance of 44.63%, while its annual performance rate touched 320.49%. The simple moving average for the period of the last 20 days is 17.06% for TGTX stocks with the simple moving average of 70.86% for the last 200 days.
Analysts’ Opinion on TG Therapeutics, Inc. (NASDAQ:TGTX)
Many brokerage firms have already submitted their reports for TGTX stocks, with JP Morgan repeating the rating for TGTX shares by setting it to “Overweight”. The predicted price for TGTX socks in the upcoming period according to JP Morgan is $38 based on the research report published on September 1, 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see TGTX stock at the price of $38, previously predicting the value of $32. The rating they have provided for TGTX stocks is “Buy” according to the report published on August 11, 2020.
Evercore ISI gave “Outperform” rating to TGTX stocks, setting the target price at $60 in the report published on June 5, 2020.
TGTX Stocks 20.40% Far from 50 Day Moving Average
After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, TG Therapeutics, Inc. was able to take a rebound, for now settling with 3.36% of profit for the given period.
The stock volatility was left at 5.27%, however, within the period of a single month, the volatility rate increased by 3.21%, while the shares surge at the distance of +26.83% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +30.34% upper at the present time.
In the course of the last 5 trading sessions, TGTX went up by +8.66%, which changed the moving average for the period of 200 days to the total of +224.26% of gains for the stock in comparison to the 20-day moving average settled at $22.37. In addition, TG Therapeutics, Inc. saw 132.97% in overturn over the period of a single year with a tendency to cut further gains.
TGTX Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at TG Therapeutics, Inc. (TGTX), starting from KENNEDY WILLIAM JAMES, who sold 7,745 shares at the price of $18.27 back on Jun 17. After this action, Rushing now owns 94,633 shares of TG Therapeutics, Inc., valued at $141,501 with the latest closing price.
TGTX Stock Fundamentals
The current profitability levels are settled at -112009.87 for the present operating margin. The net margin for TG Therapeutics, Inc. stands at -113730.92. Total capital return value is set at -328.32, while invested capital returns managed to touch -339.50. Equity return holds the value -399.60%, with -125.90% for asset returns.
Based on TG Therapeutics, Inc. (TGTX), the company’s capital structure generated 106.16 points for debt to equity in total, while total debt to capital is set at the value of 51.49. Total debt to assets is settled at the value of 25.15 with long-term debt to equity ratio rests at -41.66 and long-term debt to capital is 101.48.
The value for Enterprise to Sales is 5,799.03 with debt to enterprise value settled at 0.05. The receivables turnover for TG Therapeutics, Inc. is 3.20 with the total asset turnover at the value of 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.